Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Citalopram Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Citalopram Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Solution
  • 1.4.3 Tablets
  • 1.4.4 Other
• 1.5 Market by Application
  • 1.5.1 Global Citalopram Market Share by Application: 2020 VS 2026
  • 1.5.2 Depression
  • 1.5.3 Generalized Anxiety
  • 1.5.4 Obsessive Compulsive Disorder
  • 1.5.5 Somatoform Disorder
  • 1.5.6 Schizophrenia
  • 1.5.7 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends by Regions

• 2.1 Citalopram Market Perspective (2015-2026)
• 2.2 Citalopram Growth Trends by Regions
  • 2.2.1 Citalopram Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Citalopram Historic Market Share by Regions (2015-2020)
  • 2.2.3 Citalopram Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Citalopram Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Citalopram Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Citalopram Players by Market Size
  • 3.1.1 Global Top Citalopram Players by Revenue (2015-2020)
  • 3.1.2 Global Citalopram Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Citalopram Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Citalopram Market Concentration Ratio
  • 3.2.1 Global Citalopram Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Citalopram Revenue in 2019
• 3.3 Citalopram Key Players Head office and Area Served
• 3.4 Key Players Citalopram Product Solution and Service
• 3.5 Date of Enter into Citalopram Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Citalopram Historic Market Size by Type (2015-2020)
• 4.2 Global Citalopram Forecasted Market Size by Type (2021-2026)

5 Citalopram Breakdown Data by Application (2015-2026)

• 5.1 Global Citalopram Market Size by Application (2015-2020)
• 5.2 Global Citalopram Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Citalopram Market Size (2015-2020)
• 6.2 Citalopram Key Players in North America (2019-2020)
• 6.3 North America Citalopram Market Size by Type (2015-2020)
• 6.4 North America Citalopram Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Citalopram Market Size (2015-2020)
• 7.2 Citalopram Key Players in Europe (2019-2020)
• 7.3 Europe Citalopram Market Size by Type (2015-2020)
• 7.4 Europe Citalopram Market Size by Application (2015-2020)

8 China

• 8.1 China Citalopram Market Size (2015-2020)
• 8.2 Citalopram Key Players in China (2019-2020)
• 8.3 China Citalopram Market Size by Type (2015-2020)
• 8.4 China Citalopram Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Citalopram Market Size (2015-2020)
• 9.2 Citalopram Key Players in Japan (2019-2020)
• 9.3 Japan Citalopram Market Size by Type (2015-2020)
• 9.4 Japan Citalopram Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Citalopram Market Size (2015-2020)
• 10.2 Citalopram Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Citalopram Market Size by Type (2015-2020)
• 10.4 Southeast Asia Citalopram Market Size by Application (2015-2020)

11 India

• 11.1 India Citalopram Market Size (2015-2020)
• 11.2 Citalopram Key Players in India (2019-2020)
• 11.3 India Citalopram Market Size by Type (2015-2020)
• 11.4 India Citalopram Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Citalopram Market Size (2015-2020)
• 12.2 Citalopram Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Citalopram Market Size by Type (2015-2020)
• 12.4 Central & South America Citalopram Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 H.Lundbeck A/S
  • 13.1.1 H.Lundbeck A/S Company Details
  • 13.1.2 H.Lundbeck A/S Business Overview and Its Total Revenue
  • 13.1.3 H.Lundbeck A/S Citalopram Introduction
  • 13.1.4 H.Lundbeck A/S Revenue in Citalopram Business (2015-2020))
  • 13.1.5 H.Lundbeck A/S Recent Development
• 13.2 Amneal Pharmaceuticals
  • 13.2.1 Amneal Pharmaceuticals Company Details
  • 13.2.2 Amneal Pharmaceuticals Business Overview and Its Total Revenue
  • 13.2.3 Amneal Pharmaceuticals Citalopram Introduction
  • 13.2.4 Amneal Pharmaceuticals Revenue in Citalopram Business (2015-2020)
  • 13.2.5 Amneal Pharmaceuticals Recent Development
• 13.3 Aurobindo Pharma
  • 13.3.1 Aurobindo Pharma Company Details
  • 13.3.2 Aurobindo Pharma Business Overview and Its Total Revenue
  • 13.3.3 Aurobindo Pharma Citalopram Introduction
  • 13.3.4 Aurobindo Pharma Revenue in Citalopram Business (2015-2020)
  • 13.3.5 Aurobindo Pharma Recent Development
• 13.4 Hetero Drugs
  • 13.4.1 Hetero Drugs Company Details
  • 13.4.2 Hetero Drugs Business Overview and Its Total Revenue
  • 13.4.3 Hetero Drugs Citalopram Introduction
  • 13.4.4 Hetero Drugs Revenue in Citalopram Business (2015-2020)
  • 13.4.5 Hetero Drugs Recent Development
• 13.5 Macleods Pharmaceuticals
  • 13.5.1 Macleods Pharmaceuticals Company Details
  • 13.5.2 Macleods Pharmaceuticals Business Overview and Its Total Revenue
  • 13.5.3 Macleods Pharmaceuticals Citalopram Introduction
  • 13.5.4 Macleods Pharmaceuticals Revenue in Citalopram Business (2015-2020)
  • 13.5.5 Macleods Pharmaceuticals Recent Development
• 13.6 Silarx Pharmacueticals
  • 13.6.1 Silarx Pharmacueticals Company Details
  • 13.6.2 Silarx Pharmacueticals Business Overview and Its Total Revenue
  • 13.6.3 Silarx Pharmacueticals Citalopram Introduction
  • 13.6.4 Silarx Pharmacueticals Revenue in Citalopram Business (2015-2020)
  • 13.6.5 Silarx Pharmacueticals Recent Development
• 13.7 Apotex
  • 13.7.1 Apotex Company Details
  • 13.7.2 Apotex Business Overview and Its Total Revenue
  • 13.7.3 Apotex Citalopram Introduction
  • 13.7.4 Apotex Revenue in Citalopram Business (2015-2020)
  • 13.7.5 Apotex Recent Development
• 13.8 Hikma Pharmaceuticals
  • 13.8.1 Hikma Pharmaceuticals Company Details
  • 13.8.2 Hikma Pharmaceuticals Business Overview and Its Total Revenue
  • 13.8.3 Hikma Pharmaceuticals Citalopram Introduction
  • 13.8.4 Hikma Pharmaceuticals Revenue in Citalopram Business (2015-2020)
  • 13.8.5 Hikma Pharmaceuticals Recent Development
• 13.9 Jubilant Pharma
  • 13.9.1 Jubilant Pharma Company Details
  • 13.9.2 Jubilant Pharma Business Overview and Its Total Revenue
  • 13.9.3 Jubilant Pharma Citalopram Introduction
  • 13.9.4 Jubilant Pharma Revenue in Citalopram Business (2015-2020)
  • 13.9.5 Jubilant Pharma Recent Development
• 13.10 Lupin Limited
  • 13.10.1 Lupin Limited Company Details
  • 13.10.2 Lupin Limited Business Overview and Its Total Revenue
  • 13.10.3 Lupin Limited Citalopram Introduction
  • 13.10.4 Lupin Limited Revenue in Citalopram Business (2015-2020)
  • 13.10.5 Lupin Limited Recent Development
• 13.11 Prinston Pharmaceutical
  • 10.11.1 Prinston Pharmaceutical Company Details
  • 10.11.2 Prinston Pharmaceutical Business Overview and Its Total Revenue
  • 10.11.3 Prinston Pharmaceutical Citalopram Introduction
  • 10.11.4 Prinston Pharmaceutical Revenue in Citalopram Business (2015-2020)
  • 10.11.5 Prinston Pharmaceutical Recent Development
• 13.12 STI Pharma
  • 10.12.1 STI Pharma Company Details
  • 10.12.2 STI Pharma Business Overview and Its Total Revenue
  • 10.12.3 STI Pharma Citalopram Introduction
  • 10.12.4 STI Pharma Revenue in Citalopram Business (2015-2020)
  • 10.12.5 STI Pharma Recent Development
• 13.13 TEVA Pharmaceutical
  • 10.13.1 TEVA Pharmaceutical Company Details
  • 10.13.2 TEVA Pharmaceutical Business Overview and Its Total Revenue
  • 10.13.3 TEVA Pharmaceutical Citalopram Introduction
  • 10.13.4 TEVA Pharmaceutical Revenue in Citalopram Business (2015-2020)
  • 10.13.5 TEVA Pharmaceutical Recent Development
• 13.14 Hexal
  • 10.14.1 Hexal Company Details
  • 10.14.2 Hexal Business Overview and Its Total Revenue
  • 10.14.3 Hexal Citalopram Introduction
  • 10.14.4 Hexal Revenue in Citalopram Business (2015-2020)
  • 10.14.5 Hexal Recent Development
• 13.15 Shanghai Great Wall Pharmaceutical
  • 10.15.1 Shanghai Great Wall Pharmaceutical Company Details
  • 10.15.2 Shanghai Great Wall Pharmaceutical Business Overview and Its Total Revenue
  • 10.15.3 Shanghai Great Wall Pharmaceutical Citalopram Introduction
  • 10.15.4 Shanghai Great Wall Pharmaceutical Revenue in Citalopram Business (2015-2020)
  • 10.15.5 Shanghai Great Wall Pharmaceutical Recent Development
• 13.16 Wanquan Wante Pharmaceutical
  • 10.16.1 Wanquan Wante Pharmaceutical Company Details
  • 10.16.2 Wanquan Wante Pharmaceutical Business Overview and Its Total Revenue
  • 10.16.3 Wanquan Wante Pharmaceutical Citalopram Introduction
  • 10.16.4 Wanquan Wante Pharmaceutical Revenue in Citalopram Business (2015-2020)
  • 10.16.5 Wanquan Wante Pharmaceutical Recent Development
• 13.17 Northeast Pharmaceutical Group
  • 10.17.1 Northeast Pharmaceutical Group Company Details
  • 10.17.2 Northeast Pharmaceutical Group Business Overview and Its Total Revenue
  • 10.17.3 Northeast Pharmaceutical Group Citalopram Introduction
  • 10.17.4 Northeast Pharmaceutical Group Revenue in Citalopram Business (2015-2020)
  • 10.17.5 Northeast Pharmaceutical Group Recent Development
• 13.18 Sichuan Kelun Pharmaceutical
  • 10.18.1 Sichuan Kelun Pharmaceutical Company Details
  • 10.18.2 Sichuan Kelun Pharmaceutical Business Overview and Its Total Revenue
  • 10.18.3 Sichuan Kelun Pharmaceutical Citalopram Introduction
  • 10.18.4 Sichuan Kelun Pharmaceutical Revenue in Citalopram Business (2015-2020)
  • 10.18.5 Sichuan Kelun Pharmaceutical Recent Development
• 13.19 Kunming Jida Pharmaceutical
  • 10.19.1 Kunming Jida Pharmaceutical Company Details
  • 10.19.2 Kunming Jida Pharmaceutical Business Overview and Its Total Revenue
  • 10.19.3 Kunming Jida Pharmaceutical Citalopram Introduction
  • 10.19.4 Kunming Jida Pharmaceutical Revenue in Citalopram Business (2015-2020)
  • 10.19.5 Kunming Jida Pharmaceutical Recent Development
• 13.20 Jiangsu Enhua Pharmaceutical
  • 10.20.1 Jiangsu Enhua Pharmaceutical Company Details
  • 10.20.2 Jiangsu Enhua Pharmaceutical Business Overview and Its Total Revenue
  • 10.20.3 Jiangsu Enhua Pharmaceutical Citalopram Introduction
  • 10.20.4 Jiangsu Enhua Pharmaceutical Revenue in Citalopram Business (2015-2020)
  • 10.20.5 Jiangsu Enhua Pharmaceutical Recent Development
• 13.21 Southwest Pharmaceutical
  • 10.21.1 Southwest Pharmaceutical Company Details
  • 10.21.2 Southwest Pharmaceutical Business Overview and Its Total Revenue
  • 10.21.3 Southwest Pharmaceutical Citalopram Introduction
  • 10.21.4 Southwest Pharmaceutical Revenue in Citalopram Business (2015-2020)
  • 10.21.5 Southwest Pharmaceutical Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer

This report focuses on the global Citalopram status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Citalopram development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study
H.Lundbeck A/S
Amneal Pharmaceuticals
Aurobindo Pharma
Hetero Drugs
Macleods Pharmaceuticals
Silarx Pharmacueticals
Apotex
Hikma Pharmaceuticals
Jubilant Pharma
Lupin Limited
Prinston Pharmaceutical
STI Pharma
TEVA Pharmaceutical
Hexal
Shanghai Great Wall Pharmaceutical
Wanquan Wante Pharmaceutical
Northeast Pharmaceutical Group
Sichuan Kelun Pharmaceutical
Kunming Jida Pharmaceutical
Jiangsu Enhua Pharmaceutical
Southwest Pharmaceutical

Market segment by Type, the product can be split into
Solution
Tablets
Other
Market segment by Application, split into
Depression
Generalized Anxiety
Obsessive Compulsive Disorder
Somatoform Disorder
Schizophrenia
Other

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Citalopram status, future forecast, growth opportunity, key market and key players.
To present the Citalopram development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Citalopram are as follows:
History Year: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.